Drug
PD 0325901
PD 0325901: highest development phase Phase 2, developed by Pfizer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| PD-0325901 NCT00174369 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow PD 0325901 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.